JP2022507065A5 - - Google Patents
Info
- Publication number
- JP2022507065A5 JP2022507065A5 JP2021525223A JP2021525223A JP2022507065A5 JP 2022507065 A5 JP2022507065 A5 JP 2022507065A5 JP 2021525223 A JP2021525223 A JP 2021525223A JP 2021525223 A JP2021525223 A JP 2021525223A JP 2022507065 A5 JP2022507065 A5 JP 2022507065A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- halo
- alkoxy
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024091521A JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Applications Claiming Priority (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760209P | 2018-11-13 | 2018-11-13 | |
| US201862760248P | 2018-11-13 | 2018-11-13 | |
| US201862760244P | 2018-11-13 | 2018-11-13 | |
| US62/760,209 | 2018-11-13 | ||
| US62/760,244 | 2018-11-13 | ||
| US62/760,248 | 2018-11-13 | ||
| US201862768811P | 2018-11-16 | 2018-11-16 | |
| US62/768,811 | 2018-11-16 | ||
| US201862769151P | 2018-11-19 | 2018-11-19 | |
| US201862769165P | 2018-11-19 | 2018-11-19 | |
| US62/769,165 | 2018-11-19 | ||
| US62/769,151 | 2018-11-19 | ||
| US201962795919P | 2019-01-23 | 2019-01-23 | |
| US62/795,919 | 2019-01-23 | ||
| US201962796356P | 2019-01-24 | 2019-01-24 | |
| US201962796361P | 2019-01-24 | 2019-01-24 | |
| US62/796,361 | 2019-01-24 | ||
| US62/796,356 | 2019-01-24 | ||
| US201962836575P | 2019-04-19 | 2019-04-19 | |
| US201962836585P | 2019-04-19 | 2019-04-19 | |
| US201962836577P | 2019-04-19 | 2019-04-19 | |
| US62/836,575 | 2019-04-19 | ||
| US62/836,585 | 2019-04-19 | ||
| US62/836,577 | 2019-04-19 | ||
| US201962895595P | 2019-09-04 | 2019-09-04 | |
| US62/895,595 | 2019-09-04 | ||
| PCT/US2019/060770 WO2020102096A1 (en) | 2018-11-13 | 2019-11-11 | Compounds and compositions for treating conditions associated with nlrp activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091521A Division JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507065A JP2022507065A (ja) | 2022-01-18 |
| JP2022507065A5 true JP2022507065A5 (https=) | 2022-11-22 |
| JP7730759B2 JP7730759B2 (ja) | 2025-08-28 |
Family
ID=68841175
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525223A Active JP7730759B2 (ja) | 2018-11-13 | 2019-11-11 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
| JP2024091521A Pending JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091521A Pending JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20230031406A1 (https=) |
| EP (2) | EP3880660B1 (https=) |
| JP (2) | JP7730759B2 (https=) |
| KR (1) | KR20210096123A (https=) |
| CN (2) | CN113166065B (https=) |
| AU (1) | AU2019379109B2 (https=) |
| BR (1) | BR112021008969A2 (https=) |
| CA (1) | CA3114918A1 (https=) |
| CL (1) | CL2021001228A1 (https=) |
| CO (1) | CO2021006075A2 (https=) |
| CR (1) | CR20210235A (https=) |
| DK (1) | DK3880660T3 (https=) |
| EC (2) | ECSP21033236A (https=) |
| ES (1) | ES3042546T3 (https=) |
| FI (1) | FI3880660T3 (https=) |
| HR (1) | HRP20251344T1 (https=) |
| HU (1) | HUE073575T2 (https=) |
| IL (1) | IL283042B2 (https=) |
| JO (1) | JOP20210105B1 (https=) |
| LT (1) | LT3880660T (https=) |
| MA (1) | MA54229B1 (https=) |
| MX (1) | MX2021005529A (https=) |
| MY (1) | MY206733A (https=) |
| PE (1) | PE20211698A1 (https=) |
| PH (1) | PH12021500025A1 (https=) |
| PL (1) | PL3880660T3 (https=) |
| PT (1) | PT3880660T (https=) |
| RS (1) | RS67257B1 (https=) |
| SG (1) | SG11202103405TA (https=) |
| SI (1) | SI3880660T1 (https=) |
| WO (1) | WO2020102096A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11370776B2 (en) * | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| KR20200087759A (ko) | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CN117105890A (zh) * | 2019-11-12 | 2023-11-24 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| EP4093509A1 (en) * | 2020-01-22 | 2022-11-30 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as nlrp3 modulators |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| JP7825294B2 (ja) * | 2021-02-10 | 2026-03-06 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｎｌｒｐ３阻害剤としての化合物 |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN116635374B (zh) * | 2021-05-10 | 2025-05-06 | 康百达（四川）生物医药科技有限公司 | 酰胺衍生物及其应用 |
| WO2022237782A1 (zh) * | 2021-05-10 | 2022-11-17 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| TWI815439B (zh) * | 2021-05-10 | 2023-09-11 | 大陸商成都百裕製藥股份有限公司 | 醯胺衍生物及其應用 |
| CN114989058B (zh) * | 2022-06-02 | 2024-04-16 | 中国科学院成都生物研究所 | 一种手性氯代砜亚胺类化合物及其衍生物的制备方法 |
| CN115974745B (zh) * | 2022-12-27 | 2025-06-03 | 瑞石生物医药有限公司 | 一类含引达省的化合物及其医药用途 |
| CN116253664A (zh) * | 2023-02-01 | 2023-06-13 | 山东海科创新研究院有限公司 | 基于双液相微乳化缩合工艺的accp制备方法 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102727059B1 (ko) * | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| US11597706B2 (en) * | 2016-04-18 | 2023-03-07 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| RS65492B1 (sr) * | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| CN111094242B (zh) * | 2017-07-24 | 2024-02-09 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| EP3823974A1 (en) * | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
-
2019
- 2019-11-11 CR CR20210235A patent/CR20210235A/es unknown
- 2019-11-11 DK DK19817831.1T patent/DK3880660T3/da active
- 2019-11-11 HR HRP20251344TT patent/HRP20251344T1/hr unknown
- 2019-11-11 EP EP19817831.1A patent/EP3880660B1/en active Active
- 2019-11-11 CN CN201980074397.XA patent/CN113166065B/zh active Active
- 2019-11-11 LT LTEPPCT/US2019/060770T patent/LT3880660T/lt unknown
- 2019-11-11 JP JP2021525223A patent/JP7730759B2/ja active Active
- 2019-11-11 MY MYPI2021002584A patent/MY206733A/en unknown
- 2019-11-11 HU HUE19817831A patent/HUE073575T2/hu unknown
- 2019-11-11 RS RS20250973A patent/RS67257B1/sr unknown
- 2019-11-11 EP EP25186277.7A patent/EP4667054A3/en active Pending
- 2019-11-11 CN CN202510396657.2A patent/CN120531732A/zh active Pending
- 2019-11-11 FI FIEP19817831.1T patent/FI3880660T3/fi active
- 2019-11-11 SG SG11202103405TA patent/SG11202103405TA/en unknown
- 2019-11-11 MX MX2021005529A patent/MX2021005529A/es unknown
- 2019-11-11 AU AU2019379109A patent/AU2019379109B2/en active Active
- 2019-11-11 BR BR112021008969-1A patent/BR112021008969A2/pt unknown
- 2019-11-11 KR KR1020217017180A patent/KR20210096123A/ko active Pending
- 2019-11-11 SI SI201930974T patent/SI3880660T1/sl unknown
- 2019-11-11 PH PH1/2021/500025A patent/PH12021500025A1/en unknown
- 2019-11-11 IL IL283042A patent/IL283042B2/en unknown
- 2019-11-11 CA CA3114918A patent/CA3114918A1/en active Pending
- 2019-11-11 US US17/292,881 patent/US20230031406A1/en active Pending
- 2019-11-11 WO PCT/US2019/060770 patent/WO2020102096A1/en not_active Ceased
- 2019-11-11 PT PT198178311T patent/PT3880660T/pt unknown
- 2019-11-11 MA MA54229A patent/MA54229B1/fr unknown
- 2019-11-11 PL PL19817831.1T patent/PL3880660T3/pl unknown
- 2019-11-11 ES ES19817831T patent/ES3042546T3/es active Active
- 2019-11-11 PE PE2021000700A patent/PE20211698A1/es unknown
-
2021
- 2021-05-10 JO JOJO/P/2021/0105A patent/JOP20210105B1/ar active
- 2021-05-10 CO CONC2021/0006075A patent/CO2021006075A2/es unknown
- 2021-05-11 EC ECSENADI202133236A patent/ECSP21033236A/es unknown
- 2021-05-11 CL CL2021001228A patent/CL2021001228A1/es unknown
-
2024
- 2024-06-05 JP JP2024091521A patent/JP2024113083A/ja active Pending
- 2024-06-07 EC ECSENADI202444340A patent/ECSP24044340A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022507065A5 (https=) | ||
| JP2022505525A5 (https=) | ||
| JP2022507506A5 (https=) | ||
| JP7367169B2 (ja) | Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法 | |
| JP2022506898A5 (https=) | ||
| ES2796285T3 (es) | Indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| ES2981114T3 (es) | 8-ciano-5-piperidino-quinolinas como antagonistas de TLR7/8 y sus usos para el tratamiento de trastornos inmunitarios | |
| JP2022507505A5 (https=) | ||
| JP2024521712A5 (https=) | ||
| JP2020537657A5 (https=) | ||
| JP2022531609A (ja) | 新規メチルキナゾリノン誘導体 | |
| JP2019515952A5 (https=) | ||
| UA128160C2 (uk) | Сполуки, що інгібують rip1, а також способи їх одержання та застосування | |
| JP2019519598A5 (https=) | ||
| JP2019518071A5 (https=) | ||
| JP2021523159A5 (https=) | ||
| TW201629065A (zh) | 三唑并嘧啶化合物及其用途 | |
| KR20220035955A (ko) | Sting 작용제로서의 거대고리 화합물 및 이의 방법 및 용도 | |
| TWI870449B (zh) | 吡唑化合物，其配製物以及使用該化合物和/或配製物之方法 | |
| JP2022516075A5 (https=) | ||
| CN102438626B (zh) | 具有Aurora A选择性抑制作用的新型氨基吡啶衍生物 | |
| JP2025541228A (ja) | ピペリジニル－メチル－プリンアミンを含有する医薬組成物ならびに疾患及び状態の治療におけるその使用 | |
| WO2021237121A1 (en) | Substituted pyridines | |
| US11390613B2 (en) | Azole analogues and methods of use thereof | |
| JP7740804B2 (ja) | 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物 |